The 2nd Symposium of Global Health Products and Commercialization organized by the Epoch Financial Institute for Zhejiang Entrepreneurs was held in Hangzhou on April 27, 2019. The topic this year was “seeking the most promising star businesses in China”. Rejuven Dermaceutical was invited to present as a representative of the pre-selected emerging star businesses. In the presentation, Rejuven presented its latest project progress. Its lead product RJV001 was completing its final phase of GLP tox studies. RJV001 is currently being prepared for US IND submission as a first-in-class drug to remodel subcutaneous adipose tissues.
